Doppl SA

DOPPL SA, a Swiss biotech company founded in 2022, is specialized in human organ and disease modeling, offering an end-to-end prediction platform for preclinical drug discovery and R&D. We industrialize complex human miniature organs that mimic patient function in the dish while ensuring reproducibility and consistency across screening campaigns. DOPPL also developed software modules to predict patient responses from our lab grown human tissues. DOPPL offers a range of services for pre-clinical development, such as target identification/validation, drug identification/validation as well as toxicity assessment services. With this offering, we engage in royalty and milestone-based programs.